AMPH
Amphastar Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
21.60
▼ 0.08 (0.37%)
MARKET · —
Price
Open
21.60
Prev close
21.68
Day high
22.17
Day low
21.44
Volume
324.41K
Market cap
$918.82M
P/E (TTM)
12.78
52W range
16.65 – 31.26
Trailing performance
Returnvs SPY
1W
+3.30%
+4.7%
1M
+14.47%
+10.7%
3M
+18.94%
+15.8%
6M
-24.29%
-35.4%
YTD
-19.34%
-31.6%
1Y
-27.08%
-47.1%
3Y
-61.46%
-135.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$918.82M
Enterprise value$1.32B
Revenue (TTM)$730.02M
Gross profit$348.11M
EBITDA$194.51M
Net income$78.55M
EPS (TTM)$1.69
Free cash flow$230.10M
Total cash$290.12M
Total debt$688.32M
Book value / share$18.06
Shares outstanding42.54M
Float31.29M
Short % of float25.25%
Dividend yield—
Beta (5Y)0.90
Valuation & profitability ratios
Trailing P/E12.78
Forward P/E6.79
PEG ratio—
Price / sales—
Price / book1.20
EV / revenue1.80
EV / EBITDA6.77
Gross margin47.69%
Operating margin21.60%
Profit margin10.76%
Return on equity10.30%
Return on assets5.11%
Debt / equity89.61
Current ratio2.40
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $719.89M | $731.97M | $644.39M | $498.99M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $98.09M | $159.52M | $137.54M | $91.39M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $98.09M | $159.52M | $137.54M | $91.39M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.61 | 0.91 | +48.3% |
| Mar 2026 | 0.71 | 0.42 | -40.5% |
| Dec 2025 | 0.92 | 0.73 | -20.5% |
| Sep 2025 | 0.83 | 0.93 | +12.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.86 | 7 | $197.84M | +3.2% |
| Next quarter | 0.69 | 1 | $194.77M | +6.4% |
| Current year | 2.97 | 7 | $747.75M | +3.9% |
| Next year | 2.64 | 1 | $784.41M | +4.9% |
Analyst targets & ownership
Mean target$22.50
High target$30.00
Low target$20.00
Implied upside4.17%
Analyst count6
ConsensusHOLD
Strong buy / Buy0 / 0
Hold6
Sell / Strong sell0 / 1
Held by insiders30.82%
Held by institutions69.85%
Institutions holding308
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+433.69K
Net buying
Buy transactions
13
449.84K shares
Sell transactions
2
16.15K shares
Net transactions
+15
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
13.11M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 11, 26 | PRINS RICHARD K Director |
SELL | 7.97K | $161.85K | Direct |
| Aug 7, 26 | PETERS WILLIAM J Chief Financial Officer |
CONVERSION | 5.05K | $100.00K | Direct |
| Aug 7, 26 | PETERS WILLIAM J Chief Financial Officer |
SELL | 8.18K | $183.89K | Direct |
| Jul 9, 26 | PIERCE ANTHONY T Director |
STOCK | 7.89K | $0 | Direct |
| Jun 1, 26 | ZASLOFF MICHAEL A Director |
STOCK | 8.14K | $0 | Direct |
| Jun 1, 26 | PRINS RICHARD K Director |
STOCK | 8.14K | $0 | Direct |
| Jun 1, 26 | LEE HOWARD S Director |
STOCK | 8.14K | $0 | Direct |
| Jun 1, 26 | GERST DIANE G. Director |
STOCK | 8.14K | $0 | Direct |
| Jun 1, 26 | DEFLIN GAYLE Director |
STOCK | 8.14K | $0 | Direct |
| Jun 1, 26 | GAUGH DAVID RUSSELL Director |
STOCK | 8.14K | $0 | Direct |
| Mar 9, 26 | PETERS WILLIAM J Chief Financial Officer |
STOCK | 58.69K | $0 | Direct |
| Mar 9, 26 | ZHANG JACK YONGFENG Chief Executive Officer |
STOCK | 252.97K | $0 | |
| Mar 9, 26 | ZHOU RONG Officer |
STOCK | 39.43K | $0 | Direct |
| Mar 9, 26 | LIAWATIDEWI YAKOB Officer and Director |
STOCK | 35.45K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DEFLIN GAYLE |
Director | 19.06K | Stock Award(Grant) |
GERST DIANE G. |
Director | 31.90K | Stock Award(Grant) |
LEE HOWARD S |
Director | 159.35K | Stock Award(Grant) |
LIAWATIDEWI YAKOB |
Officer and Director | 125.38K | Stock Award(Grant) |
PETERS WILLIAM J |
Chief Financial Officer | 177.04K | Stock Award(Grant) |
PETERSEN FLOYD F |
Director | 71.37K | Sale |
PRINS RICHARD K |
Director | 37.60K | Stock Award(Grant) |
ZASLOFF MICHAEL A |
Director | 37.67K | Stock Award(Grant) |
ZHANG JACK YONGFENG |
Chief Executive Officer | — | Stock Award(Grant) |
ZHOU RONG |
Officer | 452.44K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
20.90
+3.34% from price
SMA 20
20.51
+5.31% from price
SMA 50
20.01
+7.94% from price
SMA 100
20.10
+7.48% from price
SMA 200
22.68
-4.77% from price
EMA 12
20.95
+3.10% from price
EMA 26
20.48
+5.49% from price
EMA 50
20.23
+6.80% from price
RSI (14)
62.1
Neutral
MACD (12,26,9)
0.48
Hist 0.15
ATR (14)
0.86
3.99% of price
Realised vol 30D
34.3%
Annualised
Bollinger upper
21.84
20, 2σ
Bollinger lower
19.18
20, 2σ
50 / 200 cross
Death
20.01 vs 22.68
Trend bias
Below 200
-4.77%
Risk profile
Beta vs SPY
0.61
Less volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
34.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-45.2%
Peak to trough
Max drawdown 5Y
-74.0%
Peak to trough
ATR 14
0.86
3.99% of price
Beta (reported)
0.90
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.14
Put-heavy session
Put / call open interest
0.33
Positioning, not flow
Max pain
20.00
-7.4% from spot
ATM implied vol
59.9%
Nearest strike to spot
Skew (10% OTM)
+7.3%
Puts bid over calls
Call volume
7
Contracts, this expiry
Put volume
8
Contracts, this expiry
Heaviest call OI
22.50
206 contracts
Heaviest put OI
12.50
60 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating
MT Newswires · 4d ago
The Top 5 Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call
StockStory · 8d ago
New Strong Sell Stocks for August 14th
Zacks · 8d ago
Amphastar (AMPH) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
AMPH Q2 Deep Dive: Portfolio Expansion and Pipeline Progress Drive Results
StockStory · 11d ago
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Zacks · 16d ago
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
Zacks · 16d ago
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.